CR20120016A - Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias - Google Patents

Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias

Info

Publication number
CR20120016A
CR20120016A CR20120016A CR20120016A CR20120016A CR 20120016 A CR20120016 A CR 20120016A CR 20120016 A CR20120016 A CR 20120016A CR 20120016 A CR20120016 A CR 20120016A CR 20120016 A CR20120016 A CR 20120016A
Authority
CR
Costa Rica
Prior art keywords
treatment
degenerative
inflammatory diseases
useful compound
new useful
Prior art date
Application number
CR20120016A
Other languages
English (en)
Inventor
Christel Jeanne Marie Menet
Koen Kurt Smits
Original Assignee
Galapagos Nv
Heinz Co H J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120016(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galapagos Nv, Heinz Co H J filed Critical Galapagos Nv
Publication of CR20120016A publication Critical patent/CR20120016A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Se revela un nuevo compuesto capaz de inhibir JAK; este compuesto puede prepararse como una composición farmacéutica, y puede usarse para la prevención y el tratamiento de una diversidad de afecciones en mamíferos, que incluyen humanos, que abarcan, a modo de ejemplo, sin limitación, afecciones inflamatorias, enfermedades autoinmunitarias, rechazo de trasplantes, etc.
CR20120016A 2009-06-26 2012-01-11 Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias CR20120016A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22068809P 2009-06-26 2009-06-26

Publications (1)

Publication Number Publication Date
CR20120016A true CR20120016A (es) 2012-02-09

Family

ID=42562363

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120016A CR20120016A (es) 2009-06-26 2012-01-11 Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias

Country Status (43)

Country Link
US (8) US8088764B2 (es)
EP (2) EP2445911B1 (es)
JP (2) JP5591925B2 (es)
KR (3) KR101850716B1 (es)
CN (2) CN102482273B (es)
AR (1) AR077220A1 (es)
AU (3) AU2010264633B2 (es)
BR (1) BRPI1015569B8 (es)
CA (1) CA2765985C (es)
CL (1) CL2011003247A1 (es)
CO (1) CO6491040A2 (es)
CR (1) CR20120016A (es)
CY (2) CY1119214T1 (es)
DK (2) DK3178819T3 (es)
DO (1) DOP2011000388A (es)
EA (1) EA021637B1 (es)
EC (1) ECSP12011626A (es)
ES (2) ES2766573T3 (es)
FR (1) FR21C1011I2 (es)
GB (1) GB2483424B (es)
HK (1) HK1167403A1 (es)
HR (2) HRP20170826T1 (es)
HU (3) HUE033154T2 (es)
IL (1) IL216667A (es)
LT (3) LT2445911T (es)
MA (1) MA33448B1 (es)
ME (1) ME02699B (es)
MX (1) MX344951B (es)
MY (1) MY156664A (es)
NI (1) NI201100222A (es)
NL (1) NL301096I2 (es)
NO (1) NO2021013I1 (es)
NZ (1) NZ596838A (es)
PE (1) PE20121032A1 (es)
PL (2) PL3178819T3 (es)
PT (2) PT2445911T (es)
RS (1) RS56035B1 (es)
SG (2) SG177363A1 (es)
SI (2) SI3178819T1 (es)
TW (1) TWI462920B (es)
UA (1) UA107935C2 (es)
WO (1) WO2010149769A1 (es)
ZA (1) ZA201109386B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
CA2853466A1 (en) * 2011-10-26 2013-05-02 Emily A. Stein Agents, methods, and devices for affecting nerve function
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
SG11201408123SA (en) * 2012-06-22 2015-01-29 Galapagos Nv Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
GB201302036D0 (en) * 2013-02-05 2013-03-20 Queen Mary & Westfield College Diagnosis
CA2932596A1 (en) * 2013-12-11 2015-06-18 Cephalon, Inc. Treatment of multiple sclerosis with a 1,2,4-triazolo [1,5a] pyridine derivative
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
TWI679205B (zh) 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
CN107531694A (zh) * 2015-04-13 2018-01-02 加拉帕戈斯股份有限公司 用于治疗炎性疾病的方法
SG11201708198SA (en) * 2015-04-13 2017-11-29 Galapagos Nv Methods for the treatment of cardiovascular disorders
AU2016257892A1 (en) * 2015-05-05 2017-11-09 Concert Pharmaceuticals, Inc. Deuterated filgotinib
CN105061420B (zh) * 2015-06-04 2017-09-05 南京旗昌医药科技有限公司 一种jak抑制剂的晶型及其制备方法和应用
CN104987333B (zh) * 2015-07-14 2017-01-11 苏州富士莱医药股份有限公司 一种Filgotinib的合成方法
WO2017012771A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Crystalline filgotinib sulfonic acid addition salts
WO2017012770A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Acid addition salts of filgotinib
WO2017012773A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Solid forms of filgotinib free base
CN105198878B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105198876B (zh) * 2015-09-18 2017-09-29 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物h晶型及其制备方法
CN105198880B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物a晶型及其制备方法
CN105111207B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物d晶型及其制备方法
CN105198879B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物c晶型及其制备方法
CN105111206B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物e晶型及其制备方法
CN105218539B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN105198877B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物g晶型及其制备方法
WO2017106566A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
US20170173034A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
WO2017106568A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer
CN112851682B (zh) * 2016-02-02 2022-10-25 深圳市塔吉瑞生物医药有限公司 一种取代的吡啶酰胺类化合物及其应用
TWI712604B (zh) * 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶
CN105669669A (zh) * 2016-03-04 2016-06-15 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物的a晶型、b晶型、d晶型、g晶型和m晶型及其制备方法
CN109071531A (zh) * 2016-03-21 2018-12-21 苏州晶云药物科技股份有限公司 用于治疗或预防jak相关疾病药物的盐酸盐晶型及其制备方法
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
WO2018019222A1 (zh) 2016-07-26 2018-02-01 张文燕 作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途
MX2019000694A (es) 2016-07-30 2019-07-10 Squibb Bristol Myers Co Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9).
CN107759587B (zh) * 2016-08-19 2021-01-26 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
EP3510024B1 (en) 2016-09-09 2021-11-17 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
CN107880038B (zh) * 2016-09-30 2021-09-28 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
WO2018087202A1 (en) 2016-11-10 2018-05-17 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
EA039352B1 (ru) * 2017-01-19 2022-01-17 Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. Соединение в качестве селективного ингибитора jak и его соли и терапевтическое применение
GB201702603D0 (en) 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JOP20180018A1 (ar) 2017-03-14 2019-01-30 Gilead Sciences Inc تركيبات صيدلية تتضمن مثبط jak
KR102651947B1 (ko) 2017-08-04 2024-03-26 브리스톨-마이어스 스큅 컴퍼니 Tlr7/8/9의 억제제로서 유용한 치환된 인돌 화합물
EP3661934B1 (en) 2017-08-04 2022-06-01 Bristol-Myers Squibb Company [1,2,4]triazolo[4,3-a]pyridinyl substituted indole compounds
EP3710440B1 (en) 2017-11-14 2023-04-05 Bristol-Myers Squibb Company Substituted indole compounds
DK3728252T3 (da) 2017-12-18 2023-11-13 Bristol Myers Squibb Co 4-azaindolforbindelser
SG11202005704RA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co 6-azaindole compounds
US11420973B2 (en) 2017-12-19 2022-08-23 Bristol-Myers Squibb Company Amide substituted indole compounds useful as TLR inhibitors
ES2932361T3 (es) 2017-12-19 2023-01-18 Bristol Myers Squibb Co Compuestos de indol sustituidos útiles como inhibidores de TLR
US11306092B2 (en) 2017-12-20 2022-04-19 Bristol-Myers Squibb Company Amino indole compounds useful as TLR inhibitors
CN111491918B (zh) 2017-12-20 2023-10-24 百时美施贵宝公司 芳基和杂芳基取代的吲哚化合物
AU2018390544A1 (en) 2017-12-20 2020-08-06 Bristol-Myers Squibb Company Diazaindole compounds
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
US10815227B2 (en) 2018-08-27 2020-10-27 Cadila Healthcare Limited Processes for the preparation of filgotinib
CN115029299B (zh) * 2018-11-07 2023-11-14 杭州瑞普晨创科技有限公司 JAK2抑制剂在胰岛β细胞诱导分化中的应用
WO2020177705A1 (zh) * 2019-03-05 2020-09-10 苏州科睿思制药有限公司 Filgotinib的马来酸盐晶型CSI及其制备方法和用途
US20220185816A1 (en) 2019-03-14 2022-06-16 Shanghai Synergy Pharmaceutical Sciences Co., Ltd Jak kinase inhibitor, preparation method for same, and applications thereof in field of medicine
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EA202192389A1 (ru) * 2019-03-30 2022-01-21 Юникем Лабораторис Лимитед Новый способ получения филготиниба и его промежуточных соединений
CN110204542B (zh) * 2019-05-23 2022-05-20 四川伊诺达博医药科技有限公司 一种JAK1抑制剂Filgotinib的合成方法
CN110151738A (zh) * 2019-06-03 2019-08-23 上海基科生物化学有限公司 一种Jak2抑制剂联合虎杖苷雾化剂及其制备方法和应用
IT201900020240A1 (it) 2019-11-04 2021-05-04 Advitech Advisory And Tech Sa Procedimento per la preparazione di Filgotinib e intermedi di sintesi
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN110878097B (zh) * 2019-11-29 2021-11-02 杭州科巢生物科技有限公司 菲格替尼的制备方法
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20220127900A (ko) * 2020-02-13 2022-09-20 주하이 유나이티드 라보라토리즈 컴퍼니 리미티드 Jak 키나아제 관련 질병의 치료를 위한 약물의 제조에 있어서 jak 억제제의 용도
EP4196477A1 (en) * 2020-08-17 2023-06-21 Vyne Therapeutics Inc. Tofacitinib-containing anhydrous elastomer-based gel formulations
WO2022072238A1 (en) * 2020-10-02 2022-04-07 University Of Massachusetts Targeting polycythemia vera (pv)-initiating cells by blocking leukotriene binding to their receptors
CN113773322B (zh) * 2021-11-10 2022-02-11 奥锐特药业(天津)有限公司 一种Filgotinib的制备方法
CN114409675B (zh) * 2022-01-07 2023-08-04 重庆医科大学 螺环异恶唑酮色满衍生物在制备用于治疗jak1介导的疾病药物中的用途
WO2023194842A1 (en) 2022-04-05 2023-10-12 Unichem Laboratories Limited Substituted tricyclic compounds and their use in rheumatoid arthritis

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ208996A (en) 1983-07-28 1989-08-29 American Cyanamid Co 5-substituted(1,2,4 triazpyrimidin-2-amine derivatives and pharmaceutical compositions
WO2000044722A1 (fr) 1999-01-29 2000-08-03 Chugai Seiyaku Kabushiki Kaisha Promoteurs de la chondrogenese et derives d'indolin-2-one
WO2002087620A1 (fr) 2001-04-27 2002-11-07 Chugai Seiyaku Kabushiki Kaisha Promoteurs de la chondrogenese
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
WO2004072072A1 (en) 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
ES2427046T3 (es) 2004-06-21 2013-10-28 Galapagos N.V. Métodos y medios para el tratamiento de la osteoartritis
CA2577478A1 (en) 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds
EP1799680A2 (en) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Triazolopyridine derivatives as antibacterial agents
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
CA2662074A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
EP2162445B1 (en) 2007-06-05 2013-11-27 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
JP2010533680A (ja) 2007-07-18 2010-10-28 ノバルティス アーゲー 二環ヘテロアリール化合物およびそれらのキナーゼ阻害剤としての使用
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
MX2010002312A (es) 2007-08-31 2010-03-18 Merck Serono Sa Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2727036C (en) * 2008-06-20 2017-03-21 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
MX2011012961A (es) 2009-06-05 2012-01-30 Cephalon Inc Preparacion y usos de derivados de 1,2,4-triazolo[1,5a]-piridina.
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
SG11201408123SA (en) 2012-06-22 2015-01-29 Galapagos Nv Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
SG177363A1 (en) 2012-02-28
HRP20200033T1 (hr) 2020-03-20
SI3178819T1 (sl) 2020-02-28
EA201270075A1 (ru) 2012-12-28
LT3178819T (lt) 2020-01-27
ECSP12011626A (es) 2012-02-29
AU2017204744A1 (en) 2017-07-27
US20200078365A1 (en) 2020-03-12
TW201103936A (en) 2011-02-01
CY1119214T1 (el) 2018-02-14
DOP2011000388A (es) 2012-04-15
US20150274722A1 (en) 2015-10-01
KR20180041262A (ko) 2018-04-23
ES2626908T3 (es) 2017-07-26
BRPI1015569A2 (pt) 2016-08-16
WO2010149769A1 (en) 2010-12-29
SI2445911T1 (sl) 2017-07-31
KR20120107919A (ko) 2012-10-04
HUS2100007I1 (hu) 2021-03-29
CN102482273B (zh) 2014-09-17
US20120142678A1 (en) 2012-06-07
CY1122649T1 (el) 2021-03-12
CL2011003247A1 (es) 2012-04-13
GB2483424B (en) 2012-07-18
PE20121032A1 (es) 2012-08-25
BRPI1015569B8 (pt) 2021-05-25
KR101696669B1 (ko) 2017-01-16
NO2021013I1 (no) 2021-03-23
IL216667A0 (en) 2012-02-29
EA021637B1 (ru) 2015-07-30
KR101850716B1 (ko) 2018-04-20
RS56035B1 (sr) 2017-09-29
TWI462920B (zh) 2014-12-01
US9707237B2 (en) 2017-07-18
HK1167403A1 (en) 2012-11-30
AR077220A1 (es) 2011-08-10
SG10201703497YA (en) 2017-06-29
MX344951B (es) 2017-01-12
ZA201109386B (en) 2012-08-29
MX2011013450A (es) 2012-05-08
CA2765985C (en) 2017-06-06
NL301096I1 (es) 2021-03-24
US20100331319A1 (en) 2010-12-30
MY156664A (en) 2016-03-15
FR21C1011I1 (es) 2021-05-07
GB2483424A (en) 2012-03-07
HRP20170826T1 (hr) 2017-08-25
ME02699B (me) 2017-10-20
JP2014221825A (ja) 2014-11-27
JP5591925B2 (ja) 2014-09-17
US20160296530A1 (en) 2016-10-13
GB201200457D0 (en) 2012-02-22
EP3178819B1 (en) 2019-12-04
IL216667A (en) 2015-08-31
DK2445911T3 (en) 2017-06-06
BRPI1015569B1 (pt) 2020-10-27
PL3178819T3 (pl) 2020-04-30
US8088764B2 (en) 2012-01-03
MA33448B1 (fr) 2012-07-03
US20180000831A1 (en) 2018-01-04
LT2445911T (lt) 2017-06-12
US10328081B2 (en) 2019-06-25
KR101916194B1 (ko) 2018-11-07
PT3178819T (pt) 2020-01-21
DK3178819T3 (en) 2020-01-27
US8563545B2 (en) 2013-10-22
KR20170007534A (ko) 2017-01-18
NL301096I2 (nl) 2021-04-12
AU2010264633A1 (en) 2011-12-22
CN104262337A (zh) 2015-01-07
US9309244B2 (en) 2016-04-12
CN102482273A (zh) 2012-05-30
AU2015218544A1 (en) 2015-09-17
AU2015218544B2 (en) 2017-04-27
EP2445911A1 (en) 2012-05-02
EP2445911B1 (en) 2017-03-01
HUE047478T2 (hu) 2020-04-28
PL2445911T3 (pl) 2017-08-31
US20140100220A1 (en) 2014-04-10
US20210369727A1 (en) 2021-12-02
PT2445911T (pt) 2017-06-12
CA2765985A1 (en) 2010-12-29
EP3178819A1 (en) 2017-06-14
UA107935C2 (en) 2015-03-10
LTPA2021504I1 (lt) 2021-04-12
NI201100222A (es) 2012-07-27
AU2010264633B2 (en) 2015-06-04
NZ596838A (en) 2014-01-31
JP2012530766A (ja) 2012-12-06
FR21C1011I2 (fr) 2022-03-25
US11000528B2 (en) 2021-05-11
LTC2445911I2 (lt) 2022-09-26
ES2766573T3 (es) 2020-06-12
HUE033154T2 (en) 2017-11-28
CO6491040A2 (es) 2012-07-31
US8999979B2 (en) 2015-04-07

Similar Documents

Publication Publication Date Title
CR20120016A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias
CR20110673A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias
AR086042A1 (es) Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
CO2017011851A2 (es) Compuestos novedosos
CL2015002519A1 (es) Composiciones antimicrobiales y procedimientos de uso relacionados.
CR20140583A (es) Aminotriazolopirimidina para uso en tratamiento de inflamación y composiciones farmacéuticas de la misma
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
CR20110092A (es) Nuevos compuestos utiles para el tratamiento de enfermedades degenerativas e inflamatorias
CL2012000752A1 (es) Compuestos derivados de fenilpiri(mi)dinilpirazoles para el control de microorganismos no deseados en la proteccion de plantas y compuestos intermediarios.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
AR089960A1 (es) Compuesto de imidazolopiridina para el tratamiento de enfermedades degenerativas e inflamatorias
CO6680683A2 (es) Inhibiddores de la prostaglandina e2 sintasa-1 microsómica (mpges-1) y composiciones que los contienen, útiles en el tratamiento de enfermedades inflamatorias
GT201400111A (es) Triazolopiridinas sustituidas
CO6541645A2 (es) Compuestos de indol y su uso farmaceutico
CL2013002446A1 (es) Compuestos derivados de quinolin-triazolopiridin-etilpirrolidina, como inihibidores de cinasa pim; proceso para su preparacion; compuestos intermediarios; composicion que los comprende, util para el tratamiento de una enfermedad inflamatoria o autoinmunitaria tal como esclerosis multiple y lupus, y para el tratamiento del cancer.
CL2016001266A1 (es) Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo.
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
CO6741223A2 (es) Derivados de azetidina útiles para el tratamiento de enfermedades metabólicas e inflamatorias
ECSP11011258A (es) Pirimidinas fusionadas
CL2013000455A1 (es) Compuestos derivados oxadiazol, inhibidores de la produccion de leucotrienos; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas y cancer.
MX352727B (es) Tratamiento de trastorno autoinmune al usar agonistas de rxr.
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
TW201613873A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
BR112013012571A2 (pt) composições fungicidas e métodos
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas